Related Experiment Video
Updated: Apr 21, 2026
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Dystrophin quantification: Biological and translational research implications
Karen Anthony1, Virginia Arechavala-Gomeza1, Laura E Taylor1
1From The Dubowitz Neuromuscular Centre (K.A., V.A.-G., S.T., L.F., N.J., C.A.S., J.E.M., F.M.), UCL, Institute of Child Health, London, UK; The Center for Gene Therapy (L.E.T., A.V., Y.K., K.M.F.), The Research Institute at Nationwide Children's Hospital, Columbus, OH; Institut de Myologie (G.B., M.B., T.V.), UPMC UM76, INSERM U 794, CNRS UMR 7215, Paris, France; Institute of Genetic Medicine (R.B., M.H., S.L., V.S.), Newcastle University, UK; and Prosensa Therapeutics (A.L., G.C.), Leiden, the Netherlands. V.A.-G. is currently affiliated with the Neuromuscular Disorders Group, BioCruces Health Research Institute, Barakaldo, Spain.
Quantitative immunohistochemistry and Western blotting are reliable methods for measuring dystrophin in Duchenne muscular dystrophy clinical trials. Standardized protocols ensure comparable results across laboratories, aiding therapy development.
Area of Science:
- Biochemistry
- Molecular Biology
- Clinical Trials
Background:
- Dystrophin is crucial for muscle membrane integrity.
- Accurate quantification of dystrophin is essential for Duchenne muscular dystrophy (DMD) clinical trials.
Purpose of the Study:
- To compare dystrophin quantification methods.
- To establish a consensus on reliable methods for clinical trials.
- To assess the biological significance of dystrophin measurements.
Main Methods:
- Multi-institutional collaboration comparing quantitative immunohistochemistry (IHC) and Western blotting.
- Analysis of normal and dystrophinopathy muscle biopsies.
- Standardized protocol development and assessment of inter-/intralaboratory variability.
Main Results:
- High concordance and minimal variability observed across laboratories, especially with quantitative IHC.
- Good agreement between IHC and Western blotting, with IHC showing higher sensitivity.
- Comparable mean dystrophin levels across different quantitative IHC methods.
Conclusions:
- Quantitative IHC and Western blotting are reliable biochemical outcome measures for DMD clinical trials.
- Standardized protocols enable comparable results between competent laboratories.
- Validated methodology supports development and regulatory approval of dystrophin-focused therapies.
